Avenue Therapeutics (ATXI) as of March 31, 2026 presents a balance sheet with total assets of $2.47 million, consisting almost entirely of cash and cash equivalents ($2.42 million) and prepaid/other current assets ($51K). Under the liquidation lens, the asset side yields approximately $2.42 million at 100% recovery on cash plus ~$46K on prepaids at 90%, for total liquidation asset value of roughly $2.47 million — essentially face value given the all-cash composition. Total liabilities stand at $1.27 million, all current: accounts payable and accrued expenses (third-party) of $515K plus related-party accrued expenses. No long-term debt, no operating leases, no pension obligations. Net liquidation recovery to equity is therefore approximately $1.2 million, consistent with MFFAIS-reported CLV/LLV/OLV of $1.15 million. This represents a marginal positive liquidation posture, but with an accumulated deficit of $106.2 million and a going concern qualification, the entity is entirely dependent on its cash balance. The company generated a net loss of $695K in Q1 2026 on operating cash outflows of $438K; beginning cash was $2.86 million. At the Q1 2026 burn rate of approximately $438K/quarter, the company has roughly 5-6 quarters of runway absent additional financing. The company is ineligible to use Form S-3 (delisted from Nasdaq in July 2025, now trading OTC), foreclosing the ATM facility. No financing cash flows occurred in Q1 2026 versus $2.09 million raised via ATM in Q1 2025. The sole liability-side material item is contingent off-balance-sheet milestone obligations: Revogenex ($3.0M on FDA approval of IV tramadol), Polpharma ($2.0M on FDA approval), Duke University ($15.6M total milestones for ATX-04), and InvaGen (7.5% of future financing proceeds up to $4.0M aggregate, ~$2.6M remaining). None of these are accrued on the balance sheet as they are contingent on future events. Filing discusses these in MD&A and Note 3 but does not separately tag the contingent milestone obligations in XBRL. The Fortress Founders Agreement requires annual equity issuance at 2.5% of fully-diluted equity plus 2.5% of gross financing proceeds — a recurring dilutive drain. Warrant liability (October 2022 Warrants, expiring October 2027) has a fair value of $0 at March 31, 2026, down from $1K at December 31, 2025; exercise price is $10.56 versus stock price of $0.29, rendering them economically worthless. Compared to the prior filing (10-K for fiscal year ended December 31, 2025), the balance sheet is materially unchanged in structure: cash declined $438K, liabilities are stable, and the company added the Duke ATX-04 license in February 2026 for a nominal $19K upfront, which did not move the balance sheet materially. No tangible assets, no inventory, no goodwill or intangibles are carried. Recovery posture is thin but technically positive; any incremental liability — a judgment, a milestone accelerated, or faster cash burn — would eliminate equity recovery entirely.
▼ Community Notes